The effort to utilize induced pluripotent stem cells (iPSCs) to treat Parkinson’s disease has advanced from experimental research into a historic clinical reality.

In March 2026, Japan’s Ministry of Health, Labour and Welfare made history by granting the world’s first conditional marketing approval for an iPSC-derived treatment for Parkinson’s disease, brand-named Amchepry.

Developed by Sumitomo Pharma in collaboration with Dr. Jun Takahashi at Kyoto University, this milestone represents a monumental shift from chemically managing symptoms to actively rebuilding the brain’s cellular infrastructure.

–

Source: https://tinyurl.com/Parkinsons-Health

.

.

.

#parkinsonsdiseaseremedies #parkinsonsdisease #parkinsons #dopamine #fblifestyle #parkinsonsawareness #japan